Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.9M 14B | Sales 2025 * | 35.29M 13.04B | Capitalization | 198M 73.09B |
---|---|---|---|---|---|
Net income 2024 * | -13M -4.8B | Net income 2025 * | -29M -10.71B | EV / Sales 2024 * | 5.22 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.61 x |
P/E ratio 2024 * |
-17
x | P/E ratio 2025 * |
-8.19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
1st Jan change | Capi. | |
---|---|---|
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |